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GWAS study using DNA pooling 
strategy identifies association 
of variant rs4910623 in OR52B4 
gene with anti-VEGF treatment 
response in age-related macular 
degeneration
Moeen Riaz1,2,*, Laura Lorés-Motta3,*, Andrea J. Richardson1,2, Yi Lu4, Grant Montgomery5, 
Amer Omar6, Robert K. Koenekoop7, John Chen8, Philipp Muether9, Lebriz Altay9, 
Tina Schick9, Sascha Fauser9, Dzenita Smailhodzic3, Freekje van Asten3, Eiko K. de Jong3, 
Carel B. Hoyng3, Kathryn P. Burdon10, Stuart MacGregor4, Robyn H. Guymer1,2, Anneke I. den 
Hollander3,11 & Paul N. Baird1,2
Pooled DNA based GWAS to determine genetic association of SNPs with visual acuity (VA) outcome 
in anti-vascular endothelial growth factor (anti-VEGF) treated neovascular age-related macular 
degeneration (nAMD) patients. We performed pooled DNA based GWAS on 285 anti-VEGF treated 
nAMD patients using high density Illumina 4.3 M array. Primary outcome was change in VA in Early 
Treatment Diabetic Retinopathy Study (ETDRS) letters after 6 months of anti-VEGF treatment (patients 
who lost ≥5 ETDRS letters classified as non-responders and all remaining classified as responders). 
GWAS analysis identified 44 SNPs of interest: 37 with strong evidence of association (p < 9 × 10−8), 2 
in drug resistance genes (p < 5 × 10−6) and 5 nonsynonymous changes (p < 1 × 10−4). In the validation 
phase, individual genotyping of 44 variants showed three SNPs (rs4910623 p = 5.6 × 10−5, rs323085 
p = 6.5 × 10−4 and rs10198937 p = 1.30 × 10−3) remained associated with VA response at 6 months. 
SNP rs4910623 also associated with treatment response at 3 months (p = 1.5 × 10−3). Replication of 
these three SNPs in 376 patients revealed association of rs4910623 with poor VA response after 3 and 
6 months of treatment (p = 2.4 × 10−3 and p = 3.5 × 10−2, respectively). Meta-analysis of both cohorts 
(673 samples) confirmed association of rs4910623 with poor VA response after 3 months (p = 1.2 × 10−5) 
and 6 months (p = 9.3 × 10−6) of treatment in nAMD patients.
Age-related macular degeneration (AMD) is a common complex progressive neurodegenerative disease in the 
elderly, which can lead to irreversible severe vision loss1. Vision is threatened when AMD advances to its late 
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sequelae of either geographic atrophy (GA) or choroidal neovascularization (CNV) also known as nAMD2. 
One of the most important regulators of the neovascularization process is vascular endothelial growth factor A 
(VEGF-A)3. Currently, the most effective treatment for nAMD is inhibition of VEGF through the use of recom-
binant, humanised anti-VEGF monoclonal antibodies such as ranibizumab (Lucentis), aflibercept (Eylea) or 
off-label bevacizumab (Avastin). These drugs have been shown in multiple studies4–8 to be efficacious in improv-
ing vision, but a varying response to anti-VEGF treatment has been observed. Approximately 10% of patients 
showed no improvement in visual acuity (VA) (loss of > 15 ETDRS letters), and exhibited a continuous decline in 
VA over two years of treatment similar to that previously reported for both ANCHOR and MARINA trials5,6. This 
range of variable VA response may in part be explained by genetic predisposition.
It is well established that genetic factors are associated with risk of developing AMD9. Several of the genes 
associated with AMD are also genes encoding components of the neovascularization pathway and have previ-
ously been investigated in variation to anti-VEGF treatment response studies8,10–12. However, conflicting findings 
have been reported thus far.
The current study aimed to investigate associations with genetic variants in a hypothesis-free manner using a 
genome-wide association study (GWAS). We investigated whether genetic factors influencing ranibizumab treat-
ment outcomes in nAMD patients could be identified through the initial use of a GWAS pooling strategy followed 
by a technical validation and subsequent replication in an independent cohort.
Results
The objective of this study was to investigate whether genetic variants could be identified that might influence the 
treatment outcome after anti-VEGF treatment in nAMD patients. The demographic characteristics of patients 
of the Melbourne discovery cohort and the replication cohort are shown in Table 1. A total of 297 patients from 
the Melbourne discovery cohort (285 individuals used initially in the pooled GWAS, plus an additional 12 
ranibizumab-treated AMD patients were included, giving a total of 297 individuals) and 376 patients from the 
replication cohort met the study inclusion criteria with a mean age of 79.2 years and 77.1 years, respectively. A 
mean baseline VA (at the time of first injection) of 51 ETDRS letters was observed in the Melbourne discovery 
cohort and 52.6 ETDRS letters in the replication cohort (Table 1). In the Melbourne discovery cohort, sex, smok-
ing, type of lesion, size of CNV and number of injections up to 6 months of treatment, showed no significant 
association with change in VA at 3 and 6 months of treatment (p > 0.05). Baseline VA showed a consistent nega-
tive association with change in VA at 3 and 6 months (p < 0.001) in both the Melbourne and replication cohort. 
In addition, age at the time of nAMD treatment was associated with change in VA at 3 months (p < 0.001) but 
not at 6 months in the replication cohort (p > 0.05) (Supplementary Table S1). Both the discovery and replication 






Montreal) (n = 376)
Sex
 Female 181 (60.9%) 214 (56.9%)
 Male 116 (39.1%) 162 (43.1%)
Age (years), mean ± SD Range 79.2 ± 7.1 (53–102) 77.1 ± 7.4 (53–97)
Baseline Visual Acuity (ETDRS letters), mean ± SD Range 51.0 ± 17.5 (2–88) 52.6 ± 18.0∞ (1–85)
Type of lesion
    Predominantly Classic 23% 19.4%
    Non-Predominantly Classic 77% 69.7%
    Missing Data 11% 10.9%
*+Size of CNV
    < 2 optic-disc area 44% 24.5%
    > 2 Optic-disc area 29% 51.3%
    Missing Data 27% 24.2%
Number of Injections at 6 months, mean ± SD 4.7 ± 1.3 NA
^Number of Responders/Non-responders
   3 Month 84%/16% 82%/18%
   6 Month 79%/21% 76%/24%
Table 1. Patient demographics and clinical characteristics of the Melbourne discovery cohort and the 
replication cohorts. SD = Standard Deviation, ETDRS = Early Treatment Diabetic Retinopathy Study, *In the 
discovery cohort, one optic-disc area is equal to 2.54 mm2, based on an optic disc diameter of 1.8 mm, +In the 
replication cohort optic disc measurement is based on each patient optic disc area, NA = Not available, ^Non-
responders classified as those who showed loss of ≥ 5 EDTRS letters VA from baseline; all remaining patients 
were classified as responders. ∞For 303 patients, Snellen visual values were first converted into approximate 
ETDRS letters using a chart that has all three measurement to read the equivalent number of ETDRS letters. It is 
based on formula ETDRS letters = 85 − ((− (logSnellen))/0.02)40.
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First Phase- Genome wide association Study. First phase results from the pooled GWAS are shown in a 
Manhattan plot in Fig. 1. A total of 44 SNPs from the pooled GWAS were selected for technical validation through 
independent individual genotyping on the basis of a genome-wide significant p-value (37 SNPs, p < 9 × 10−8), 
SNPs in genes involved in drug resistance response (‘pharmagenes’) (2 SNPs, p < 5.0 × 10−6) and SNPs leading to 
a missense change in a coding region of a gene (5 SNPs, p < 1.0 × 10−4) (Table 2).
Second Phase- Validation. In the second phase, all 44 SNPs from the first phase were genotyped in 297 
patients (the same cohort as in phase 1 but with the addition of 12 extra patient samples who became available 
between the time of phase1 and phase2). This individual genotyping confirmed the 3 SNPs (rs4910623, rs323085, 
rs10158937) to be significantly associated (p < 0.05) with response at 6 months of ranibizumab treatment after 
Bonferroni correction for 44 independent tests. SNP rs4910623 showed the highest significance (p = 5.7 × 10−5), 
in which the ‘G’ risk allele led to a worse response (OR = 2.58 [95% CI = 1.63–4.10]). While the C allele of both 
rs323085 and rs10158937 (p = 6.5 × 10−4 and p = 1.30 × 10−3, respectively) appeared protective (OR = 0.16 [95% 
CI = 0.06–0.46] and OR = 0.32 [95% CI = 0.17–0.65], respectively) (Table 3).
Since a loading dose of three monthly injections is prescribed to all patients, we determined if the effect 
of these three selected SNPs in treatment outcome could be seen at this time point. The G allele of rs4910623 
showed an association with worse outcome at three months of treatment (p = 1.5 × 10−3, OR = 2.23 [95% 
CI = 1.36–3.66]).
SNP rs10158937 also showed an association with the C allele leading to a better response after 3 months 
(p = 9.0 × 10−3, OR = 0.36 [95% CI = 0.17–0.77]), consistent with the six months result. However rs323085 did 
not show significant association at three months (Table 3).
Third Phase- Replication. In the third phase, we analysed the association of the three SNPs with treat-
ment outcome in a replication cohort of European descent, consisting of 215 ranibizumab-treated AMD 
patients following pro re nata treatment protocol. The effect of rs4910623 replicated at six months of treatment 
(p = 3.5 × 10−2, OR = 1.71 [95% CI = 1.04–2.80]). At the 3 month treatment time point all replication patients 
were included in the analysis (n  =  376) as they were all treated in a similar manner to the discovery cohort. 
The effect of this SNP on treatment response was also similar at this time point (p = 2.4 × 10−3, OR = 1.8 [95% 
CI = 1.24–2.71]). SNPs rs323085 and rs10158937 were not associated with treatment response in the replication 
cohort (Table 4).
The frequency of rs4910623 risk allele (G) in the Melbourne discovery cohort was 71% and 72% for the 
non-responder group (3 and 6 months respectively) in comparison to 51% and 49% in the responders group (3 
and 6 months, respectively) (Table 3). A similar change in allele frequency was also seen in the replication cohort 
with the frequency of the risk allele G being 62% and 38% in the non-responder group compared to 48% and 52% 
in the responders group (3 and 6 months (pro re nata patients), respectively) (Table 4). The overall distribution of 
change in VA corresponding to each genotype of rs4910623 in both cohorts is shown in Fig. 2.
Meta-Analysis. A meta-analysis of SNP rs4910623 in both the Melbourne discovery cohort and the rep-
lication cohort showed differences in allele distribution between responders and non-responders at 3 months 
(p = 1.21 × 10−5) and 6 months (p = 9.3 × 10−6) of treatment (only pro re nata patients from the replication 
cohort were included) indicating the influence of rs4910623 on outcome of ranibizumab treatment in AMD 
patients (Table 5).
Figure 1. Manhattan plot of SNPs tested in a pooled GWAS for response to anti-VEGF treatment. The 
X-axis indicates the chromosomal position of the SNPs and the Y-axis shows their corresponding p-value 
(− log10). The red line indicates the threshold for genome-wide significance (p < 5 × 10−8) and the blue line 
indicates the threshold for suggestive association (p < 1 × 10−5).
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Discussion
We sought to identify genetic variants that influence the ranibizumab treatment response in AMD. Using 
a pooled DNA GWAS approach, we identified SNP rs4910623 in the promoter region of the OR52B4 gene as 
SNP Chr. Position+ Gene
Effect 
Allele Pooled GWAS Technical Replication
Pooled GWAS SNPs reaching P ≤ 9 × 10−8 P Value OR P Value OR (95% CI)
rs4910623 11 4389639 OR52B4 G 3.69 × 10−9 3.14 5.65 × 10−5 2.58 (1.63–4.10)
rs323085 18 49290621 LOC100287225 C 3.29 × 10−8 0.22 6.53 × 10−4 0.16 (0.06–0.46)
rs10158937 1 66144876 LEPR C 5.36 × 10−8 0.28 1.30 × 10−3 0.32 (0.17–0.65)
rs2475779 5 157541895 CLINT1 T 1.59 × 10−9 0.29 1.36 × 10−3 0.40 (0.23–0.70)
rs59741976 3 74593662 CNTN3 T 2.65 × 10−8 0.32 1.84 × 10−3 0.31 (0.15–0.65)
rs4655583 1 66155407 LEPR A 1.37 × 10−8 0.28 2.38 × 10−3 0.34 (0.17–0.69)
rs7857431 9 132529504 PTGES T 3.36 × 10−8 0.25 4.58 × 10−3 0.12 (0.03–0.53)
rs794009 4 40139719 N4BP2 A 6.91 × 10−8 0.35 5.47 × 10−3 0.40 (0.22–0.77)
rs10234065 7 19547138 TWISTNB T 1.37 × 10−8 0.31 5.61 × 10−3 0.13 (0.03–0.56)
rs1447830 3 74613171 CNTN3 T 7.56 × 10−9 0.30 5.63 × 10−3 0.35 (0.17–0.74)
rs2110470 7 19509870 TWISTNB A 3.35 × 10−8 0.35 5.65 × 10−3 0.40 (0.21–0.77)
rs1892535 1 66097181 LEPR T 6.50 × 10−8 0.31 6.50 × 10−3 0.38 (0.19–0.77)
rs1573317 18 382268 COLEC12 T 1.11 × 10−9 0.27 7.60 × 10−3 0.36 (0.18–0.77)
rs13154178 5 42828101 SEPP1 A 2.09 × 10−8 0.36 8.20 × 10−3 0.49 (0.30–0.83)
rs4909963 11 11119228 GALNTL4 T 9.85 × 10−9 0.24 8.32 × 10−3 0.20 (0.06–0.67)
rs79966776 3 74582701 CNTN3 A 1.61 × 10−8 0.32 9.72 × 10−3 0.42 (0.22–0.81)
rs510549 3 111700305 ABHD10 T 1.60 × 10−9 0.34 1.07 × 10−2 0.53 (0.33–0.87)
rs6917419 6 27243480 PRSS16 T 3.80 × 10−8 0.33 1.41 × 10−2 0.32 (0.13–0.80)
 rs12117294 1 209814879 LAMB3 T 1.89 × 10−8 0.34 1.84 × 10−2 0.46 (0.25–0.88)
rs10767060 11 23468443 LOC100500938 T 8.72 × 10−8 0.38 2.23 × 10−2 0.58 (0.37–093)
rs17770298 9 101208288 GABBR2 A 7.44 × 10−9 0.18 2.40 × 10−2 0.19 (0.05–081)
rs11131078 3 7548067 GRM7 T 3.23 × 10−9 0.13 2.63 × 10−2 0.58 (0.37–0.94)
rs292998 5 58032485 RAB3C G 3.86 × 10−9 0.38 2.94 × 10−2 0.61 (0.39–0.95)
rs772433 2 7838257 LOC339788 A 5.06 × 10−8 0.36 4.24 × 10−2 0.62 (0.40–0.98)
rs3806586 2 128433897 LIMS2 T 1.16 × 10−9 0.26 4.96 × 10−2 0.52 (0.28–1.00)
rs9644866 9 2290590 SMARCA2 T 3.72 × 10−9 0.17 5.60 × 10−2 0.63 (0.40–1.01)
rs10050214 4 78733015 CNOT6L T 4.22 × 10−8 0.38 6.35 × 10−2 0.40 (0.28–1.04)
rs12638297 3 29748169 RBMS3 T 4.29 × 10−8 0.31 6.40 × 10−2 0.50 (0.25–1.04)
rs4449299 3 14598965 GRIP2 A 5.50 × 10−8 0.39 8.79 × 10−2 0.64 (0.39–1.07)
rs1353892 12 90716019 C12orf37 T 1.06 × 10−9 0.34 9.71 × 10−2 0.67 (0.42–1.07)
rs659910 11 131769454 NTM T 1.27 × 10−8 0.39 1.67 × 10−1 0.71 (1.00–1.03)
rs10141328 14 96752555 ATG2B C 7.78 × 10−8 0.16 1.90 × 10−1 0.73 (0.47–1.16)
rs9323992 14 98649816 C14orf64 T 4.59 × 10−8 0.38 5.14 × 10−1 0.84 (0.50–1.41)
rs7432690 3 77450363 ROBO2 T 9.91 × 10−10 0.14 6.81 × 10−1 1.09 (0.72–1.67)
rs141659302 11 128802177 TP53AIP1 T 3.79 × 10−8 0.41 9.99 × 10−1 0.74 (0.00–0.00)
rs7320683 13 71787948 DACH1 A 5.38 × 10−8 2.86 1.00 1 (− )
rs291477 3 73807858 PDZRN3 G 1.85 × 10−10 2.91 1.00 1 (− )
Pooled GWAS SNPs in known pharmagenes showing suggestive significance
rs3804938 3 7550294 GRM7 C 1.35 × 10−7 0.13 1.01 × 10−2 0.54 (0.34–0.87)
rs4148732 7 87234049 ABCB1 G 2.72 × 10−6 0.22 1.00 × 10−3 0.08 (0.02–0.38)
Pooled GWAS SNPs leading to a missense change in gene
rs3877899 5 42801268 SEPP1 A 9.02 × 10−7 0.36 1.15 × 10−3 0.34 (0.18–0.66)
rs34677 5 33998768 AMACR T 3.22 × 10−5 0.35 3.0 × 10−3 0.26 (0.11–064)
rs3784588 15 31294654 TRPM1 T 4.73 × 10−5 0.27 9.96 × 10−1 0.04 (1.00–1.03)
rs17659179 18 47511113 MYO5B A 8.20 × 10−5 0.28 4.75 × 10−2 0.29 (0.09–0.99)
rs17673268 9 368128 DOCK8 T 1.54 × 10−5 0.41 2.44 × 10−1 0.63 (1.00–1.03)
Table 2. Selected SNPs from the pooled GWAS comparing responders and non-responders at 6 months 
ranibuzimab treatment and validation results using an independent genotyping technique in the 
Melbourne discovery cohort. For technical replication P values were calculated using logistic regression 
adjusted for baseline visual acuity, OR = odds ratio, SNP: single nucleotide polymorphism, Chr: chromosome, 
BP: base pair position on chromosome. SNPs that remained significantly associated after Bonferroni correction 
for multiple testing are highlighted in bold. +Representing position from phase 3 1000 G CEU reference panel.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:37924 | DOI: 10.1038/srep37924
being associated with a worse response to ranibizumab treatment. The association was validated in the same 
cohort through individual genotyping and confirmed in an independent replication cohort of AMD patients 
of European descent. Individuals carrying the risk allele G did not respond as well to ranibizumab treatment in 
either cohort after 3 or 6 months of treatment compared to those with the A allele. In the replication cohort we 
observed significant association of rs4910623 with change in VA in patients on pro re nata treatment regimen 
at 6 months. However, 47 patients from Montreal were not included in this analysis as they followed a treat and 
extend regimen. We undertook an additional sensitivity analysis where these 47 patients were included back into 
the 6 month analysis time point to provide a total of 262 patients. A similar trend for association of the G allele of 
rs4910623 was seen (p = 4.6 × 10−2, OR = 1.53 [95% CI = 1.00–2.30]). As this group consisted of only 47 patients 
it was too small to draw any conclusive conclusions about whether this treatment protocol significantly affected 
the association of the G allele of rs4910623 with change in VA. In the meta-analysis we found significant associa-
tion of rs4910623 patients with change in VA at both 3 and 6 months of treatment.
Two other SNPs, rs323085 and rs10158937, located 202 kb 3′ of LOC100287225and 42 kb at 3′ of LEPR gene 
respectively, did not remain associated with change in VA after replication. The inconsistency in the results for 
these two SNPs could indicate that they are false positive findings.
The baseline characteristics of both the Melbourne discovery and replication cohort did not reveal significant 
association with change in VA except for the baseline VA at 3 and 6 months of treatment. Baseline VA is negatively 
associated with change in VA, thus lower baseline VA will lead to a greater VA gain after treatment and vice versa. 
Therefore our findings are in agreement with the ANCHOR and MARINA trials where higher VA at baseline was 
associated with a smaller gain in VA at 12 and 24 months of treatment, respectively13. This in-turn reflects a floor 
and ceiling effect of baseline VA14. Based on definition of response in our study it may have floor effect of baseline 
VA where individuals with higher baseline VA will have limited chance to gain vision after the treatment and 
vice versa. On the other hand, the baseline VA is also reported as one of the predictors of treatment outcome for 
ranibizumab15. To overcome these potential issues we incorporated baseline VA as a covariate into our analysis. 
However, there was a difference in baseline CNV size in the discovery and replication cohort. This is probably due 
to differences in measurements between the cohorts with the Melbourne discovery cohort being based on one 
optic-disc area is equal to 2.54 mm2, using an optic disc diameter of 1.8 mm whereas the replication cohort was 
based on each patient’s optic disc area.
Using the HaploReg database16, SNP rs4910623 is predicted to alter the GATA and TCF4 regulatory motifs 
22 bp upstream of the OR52B4 gene. We also analysed the surrounding variants within its linkage disequilibrium 
(LD) block from the 1000 Genomes Project (r2 = 0.8, 250 Kb). A number of the identified SNPs in this LD block 
are predicted to alter transcriptional binding sites (Supplementary Table S3). Thus, this region may play an impor-
tant role in transcriptional regulation of this gene.
The OR52B4 protein (Q8NGK2, UniprotKB accession number) consists of 314 amino acids (aa) and is a 
member of the G-coupled protein receptor (GPCR) family, which is located in the plasma membrane of the 
cell. Interestingly we find the conserved domain of Q8NGK2 17 is a 7-transmembrane domain (7tm) region 
which is highly conserved with the 7tm_4 super family domain of all the olfactory receptors (33–321 aa) and 
also the 7tm_1 domain of the 7 transmembrane receptor (rhodopsin family) (43–294 aa) as indicated using the 
NCBI Conserved Domain Database (CCD). (http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi?seqinput= 
NP_001005161.2). Rhodopsin is also member of GPCR family and it functions to capture photons of light and 
trigger the intra-cellular photo-transduction cascade, forming the molecular basis of vision18. GPCRs are highly 
selective and expressed in specific tissues and cells, making them particularly important as potential drug targets 
as > 50% of therapeutic agents in the market target these receptors19.
To assess expression of the OR52B4 gene in human eye tissue, we used online resource: “The Ocular Tissue 
Database”20. Expression of the OR52B4 gene was present in the retina, optic nerve and choroid (Supplementary 
Table S4). The identification of olfactory gene expression in the eye is relatively new, but not surprising, as21 recently 
6 Month 
SNP A1 A2
Genotype frequency* Allele frequency +
P-Value OR 95% CIResponders Non-responders Responders Non-Responders
rs4910623 G A 0.23/0.52/0.25 0.54/0.36/0.10 0.49/0.51 0.72/0.28 5.7 × 10−5 2.58 (1.63–4.10)
rs323085 C T 0.30/0.28/0.69 0/0.70/0.93 0.17/0.83 0.03/0.97 6.5 × 10−4 0.16 (0.06–0.46)
rs10158937 C A 0.06/0.33/0.61 0/0.17/0.83 0.23/0.77 0.08/0.92 1.3 × 10−3 0.32 (0.17–0.65)
3 Month
rs4910623 G A 0.25/0.51/0.24 0.52/0.37/0.11 0.51/0.49 0.71/0.29 1.5 × 10−3 2.23 (1.36–3.66)
rs323085 C T 0.02/0.25/0.73 0.02/0.22/0.76 0.14/0.86 0.13/0.87 0.81 0.92 (0.47–1.81)
rs10158937 C A 0.06/0.33/0.62 0.02/0.13/0.85 0.22/0.78 0.09/0.91 9.0 × 10−3 0.36 (0.17–0.77)
Table 3.  Genotypic distribution and allele frequency of rs4910623, rs323085 and rs10158937 and 
association with VA response at six and three months of anti-VEGF treatment in the Melbourne discovery 
cohort. Definition of response was the same as in the pooled GWAS: Non-responders are patients who lost  
≥ 5 ETDRS letters and the remainder were classified as responders P-Value: Calculated using logistic regression 
adjusted for baseline visual acuity, OR = odd ratio, representing trend per copy effect of risk or minor allele on 
VA outcome, highlighted in bold for each SNP, CI: Confidence Interval, *Genotype frequency A1A1/A1A2/
A2A2, +Allele frequency A1/A2.
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published expression profiling of a number of olfactory receptors (olfr) in mouse cornea, retina and choroid. Their 
analysis of eye tissue expression confirmed the presence of many olfr, with one of them, olfr547 representing a 
homolog of the human OR52B4 gene (85% identity). Interestingly, olfr547 is a close relative of olfr78, which has 
recently been shown to function in regulation of blood pressure in smooth muscle cells22,23. Expression of genes in 
the olfr pathway in mouse ocular tissues is mediated by the olfaction specific Gα protein, localised in the nuclear 
layer of the retina and previously thought to be only expressed in the olfactory epithelium21. Moreover, olfactory 
genes have been shown to be associated with cancer and other blood diseases, suggesting expression and func-
tion of olfactory proteins in a number of different pathways23–25. Interestingly, another olfactory receptor (OR10J5) 
was recently reported by Kim and colleagues26 to control cell migration and phosphorylation of signaling during 
6 Month++
SNP A1 A2
Genotype frequency* Allele frequency+
P-Value OR 95% CIResponders Non-responders Responders Non-Responders
rs4910623 G A 0.24/0.48/0.28 0.34/0.54/0.12 0.48/0.52 0.62/0.38 3.5 × 10−2 1.71 (1.04–2.80)
rs323085 C T 0.02/0.25/0.74 0.00/0.21/0.79 0.14/0.86 0.10/0.90 0.46 0.74 (0.34–1.63)
rs10158937 C A 0.05/0.32/0.63 0.02/0.30/0.67 0.21/0.79 0.17/0.83 0.58 0.84 (0.45–1.57)
3 Month
rs4910623 G A 0.22/0.50/0.28 0.39/0.46/0.15 0.47/0.53 0.62/0.38 2.4 × 10−3 1.83 (1.24–2.71)
rs323085 C T 0.03/0.24/0.73 0/0.23/0.77 0.15/0.85 0.11/0.89 0.34 0.74 (0.50–1.33)
rs10158937 C A 0.04/0.32/0.64 0.06/0.35/0.59 0.20/0.80 0.23/0.77 0.25 1.31 (0.83–2.06)
Table 4.  Genotypic distribution and allele frequency of rs4910623, rs323085 and rs10158937 and 
association with VA response at six and three months of anti-VEGF treatment in the replication cohort. 
Definition of response was the same as in the pooled GWAS: Non-responders are patients who have lost  
≥ 5 ETDRS letters and the remainder were classified as responders P-Value: Calculated using logistic regression 
adjusted for baseline visual acuity and age, OR = odd ratio, representing trend per copy effect of risk or minor 
allele on VA outcome, highlighted in bold for each SNP, CI: Confidence Interval, *Genotype frequency A1A1/
A1A2/A2A2, +Allele frequency A1/A2. ++In replication cohort pro re nata treated patients included n = 215.
Figure 2. Mean change in visual acuity (VA) after three and also the six month time period (pro re nata 
treated only) of treatment stratified by rs4910623 genotype for the Melbourne discovery and replication 
cohorts. Vertical lines represent the standard error (SE) of the mean change in VA.
Meta-Analysis
SNP Gene A1 A2
3 Month 6 Month*
P value N Direction Z score P value N Direction Z score
rs4910623 OR52B4 G A 1.2 × 10−5 673 + + 4.37 9.3 × 10−6 512 + + 4.43
Table 5. Meta-analysis of the Melbourne discovery cohort and the replication cohort for SNP rs4910623 
at 3 and 6 months of ranibizumab treatment in AMD patients. Meta-analysis was performed using METAL. 
*AT 6 month only pro re nata treated patient were included from replication cohort.
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angiogenesis in mice. However the functional role of OR52B4 gene in angiogenesis needs to be elucidated and it has 
so far not previously been reported to be associated with pharmacogenetic response to AMD.
Previous studies investigating genetic factors in anti-VEGF treatment outcome have assessed known AMD 
risk-associated genes and genes encoding components of the neovascularization pathway8,10–12. However, most 
of these studies have produced variable results; for example, the Y402H variant in the CFH gene has been asso-
ciated with poor VA outcome in some studies but in other studies has been reported to show no association 
with VA. Similarly, inconsistent results of association were reported for ARMS2/HTRA1 11,27. Our pooled GWAS 
findings did not identify genome-wide significance for SNPs in the previously associated known AMD risk genes 
CFH, VEGF-A, HTRA1/ARMS2 (Supplementary Table S5). These findings are in agreement with our previous 
study28 and the CATT study, the largest current cohort in which major AMD risk alleles have been investigated 
for treatment outcome following treatment with bevacizumab, where no association with the CFH, VEGF, 
VEGFR2 and HTRA1/ARMS2 genes was identified with anti-VEGF treatment response11,12. To date, only one 
prior GWAS has been undertaken to identify genetic risk factors for treatment response to AMD. That study 
was conducted on 65 patients and reported the SNP rs7607942 near the ERBB4 gene to be associated with poor 
VA outcome after 6 months of treatment, although this SNP did not reach genome-wide significance (uncor-
rected p = 6.692 × 10−6)29. Major drawbacks of that study were the small sample size and lack of replication of the 
reported association in an independent ranibizumab-treated AMD cohort. We did not find any association of this 
SNP in the current study (p > 0.05).
We chose to use a pooled DNA GWAS strategy to investigate response to anti-VEGF treatment in AMD as 
this provided a cost-effective and efficient approach to identify genetic associations23,30–33. We were able to tech-
nically validate ~70% of the 44 SNPs that were identified in the pooling strategy at a nominal significance level. 
Whilst most SNPs replicated, the level of significance of the SNPs diminished following technical validation. 
Possible explanations for the diminished significance may be due to experimental error during pool construction, 
array-specific errors resulting from the use of a limited number of arrays per pool, variation in allele frequency 
due to small sample size in some of the pools, allele-specific bias skewing the results for some SNPs, and/or small 
differences in the set of samples used in the validation stage34,35.
For the replication cohort, the number of injections at 6 month of treatment was not available, however it is 
interesting to note that a variation in treatment regime through change in number of injections between 3 and 
6 months does not appear to ameliorate the genetic effect seen in the current study. However, after individual 
genotyping, replication and meta-analysis, SNP rs4910623 remained associated with worse functional outcome 
(change in VA) after the anti-VEGF treatment in AMD. Currently there is much interest in the role of anatom-
ical features such as fluid clearance as a measure of treatment response. However, it was not considered in this 
analysis but this would be useful to examine in the future as to whether this SNP also affects fluid clearance and 
central macular thickness (CMT) on OCT following anti-VEGF treatment. To our knowledge, SNP rs4910623 
and the 2 other SNPs associated with good response in the discovery phase have not previously been reported as 
associated with anti-VEGF treatment outcome in any type of cancer, thus it will be interesting to investigate the 
role of these SNPs in cancer following anti-VEGF treatment. Furthermore, much work needs to be undertaken 
to examine the biological basis of this phenomenon as well as the functional role of OR52B4 gene in models of 
angiogenesis, such studies could lead to the development of other therapies for AMD patients that can be used as 
an adjunct to existing treatment. This, in turn, offers the prospect of personalising treatment, based on genotype 
and opens up the route for exploring other drug treatment opportunities. In conclusion, we report for the first 
time a pooled DNA based GWAS on pharmacogenetic response to ranibizumab treatment in AMD that identifies 
association of variant rs4910623 in the OR52B4 gene. This finding was replicated in an independent replication 
cohort, suggesting that this gene may be involved in the response to anti-VEGF treatments in AMD patients of 
European decent. Finally, our data suggests that the SNP rs4910623 could be used as a diagnostic genetic marker 
before anti VEGF treatments for AMD.
Methods
Patient Recruitment and Data Collection. Melbourne Discovery Cohort. The study was approved by 
the Human Research and Ethics Committee of the Royal Victorian Eye and Ear Hospital (RVEEH) and per-
formed in accordance to the tenets of the Declaration of Helsinki (7th revision). Written informed consent was 
obtained for all study participants before participation. Patients were included in the study when they were > 50 
years of age, presented with an active sub-foveal CNV secondary to AMD, and received intravitreal anti-VEGF 
injections. Neovascularization was confirmed by fundus photography (Canon CR6-45NM; Canon Saitama, 
Japan), fundus fluorescein angiography (FFA) using IMAGEnet 2000 (Topcon Corporation, Tokyo, Japan), and 
optical coherence tomography (OCT) with Stratus OCT version 5.0.1 (Carl Zeiss Meditec, Dublin, CA) or Cirrus 
HD-OCT version 6.0.0.599 (Carl Zeiss Meditec). Exclusion criteria were nAMD associated with non-AMD con-
ditions such as degenerative myopia, angioid streaks and hereditary retinal disorders. In addition bilateral nAMD 
patients who had different VA response between both eyes and treatment with either laser photocoagulation or 
photodynamic therapy before anti-VEGF treatment as previously reported were also excluded36. Initially a total 
of 315 nAMD patients were retrospectively recruited from the medical retinal clinic of the RVEEH. A total of 297 
patients meet the eligibility criteria consisting of 277 patients with unilateral nAMD and 20 patients with bilateral 
nAMD who had the same (either gain or loss) VA response in both eyes. A total of 18 bilateral patients did not 
meet the eligibility criteria because they had differing VA response in both eyes.
VA was measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart at 4-metre distance at 
each visit. The majority of nAMD patients were treated with monthly ranibizumab injections (Lucentis; Novartis 
Pharma AG, Basel, Switzerland) for 3 months of initial dosing except for 27 (9.0%) patients who first received a 
single injection of bevacizumab (Avastin; Roche, Basel, Switzerland) who then went on to receive normal dos-
ing using ranibizumab. After 3 monthly injections, pro re nata treatment regimen were adopted for follow-up 
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injections, that was based on evaluation by a retinal specialist, who considered loss of VA ≥ 5 EDTRS letters, the 
presence of fluid on an OCT scan or presence of chronic or new retinal haemorrhage as criteria for treatment. 
Data on demographics and clinical history (including VA and treatment regimens) were collected for all partic-
ipating patients.
Replication Cohort. Ethical approval for the replication cohort was obtained from the local ethic committees 
of the Radboud university medical center, University of Cologne, and McGill University Health Centre. Written 
informed consent was acquired from all participants.
The replication cohort consisted of 376 treatment naïve patients of European descent with choroidal neovas-
cularization secondary to AMD. Patients were diagnosed by retinal specialists based on ophthalmic examination, 
spectral-domain OCT (Spectralis HRA + OCT, Heidelberg Engineering, Heidelberg, Germany) or fluorescein 
angiography (FA) (Spectralis HRA + OCT, Heidelberg Engineering, Heidelberg, Germany; or Imagenet, Topcon 
Corporation, Tokyo, Japan). All included patients were over the age of 50 years, had not undergone any previous 
ophthalmic surgery, except for cataract removal, and did not have other retinal disorders besides AMD.
A total of 144 patients were treated at the Department of Ophthalmology of the Radboud university medical 
centre, Nijmegen, the Netherlands and 182 at the University of Cologne, Germany. These patients were included 
in the European Genetic Database (EUGENDA), a multicenter database for the clinical and molecular analysis 
of AMD. The remaining 50 patients were treated at the McGill University Health Center, Montreal, Canada. All 
patients received the loading dose of three consecutive monthly intravitreal injections of 0.5 mg ranibizumab 
(Lucentis; Novartis Pharma AG, Basel, Switzerland). Afterwards, they were followed up monthly and treated 
on a pro re nata regimen at the clinics of Nijmegen and Cologne and on a treat-and-extend regimen at the clinic 
of Montreal. In Nijmegen and Cologne (pro re nata regimen), in cases of persistence or recurrence of choroidal 
neovascularization, which was defined as loss of VA of ≥ 5 ETDRS letters, leakage seen on FA, fluid seen by OCT, 
or new macular hemorrhage or fluid, three consecutive monthly ranibizumab injections were administered. VA 
was assessed before treatment and after the three loading injections for all patients. VA was also recorded after 6 
months of treatment for 262 patients. For 303 patients, Snellen VA measurements were recorded retrospectively 
and 73 patients were followed up prospectively using ETDRS VA. Baseline variables were collected using ques-
tionnaires or retrieved from the patient files. One eye was selected per patient; if both eyes received treatment, the 
first eye treated was selected and if treatment started simultaneously, the study eye was chosen randomly.
First phase - Pooled DNA Based GWAS in the Melbourne Discovery Cohort. In the first phase of 
the study, a GWAS using a DNA pooling approach was conducted (Macgregor et al.37). A peripheral blood sample 
was collected from each patient and DNA was extracted (Qiagen, Victoria, Australia). Genomic DNA was quan-
tified by Nanodrop Specrophotometer (Thermo Scientific) for a DNA concentration ≥ 175 ng/μ l. A total of 285 
samples were selected for the pooling cohort (12 samples were excluded due to a low DNA concentration required 
for pooling). Each pool was given a unique ID number, based on presenting VA. Non-responders from each pool 
were classified as those who showed loss of ≥ 5 EDTRS letters VA following 6 months of ranibizumab treatment 
and all remaining patients were classified as responders. Six equimolar DNA pools were generated with a pool size 
varying from 9 to 133 samples (Supplementary Table S2). An equal amount of DNA from each sample (varying 
from 0.2 μ g to 0.6 μ g) was added to the appropriate pool, with a minimum volume of 5 μ l per sample to reduce 
pipetting errors at low volume. Pooled genomic DNAs were assayed using an Illumina Human Omni5-Quad 
Bead Chip that captured 4.3 million SNP markers. We randomised the pooled samples on the genotyping arrays 
to avoid spurious associations that may arise from array position. Approximately 4,600 indels or copy number 
variants were removed from the analyses. We applied stringent quality control (QC) as previously described (Lu 
et al.38). Briefly, we excluded SNPs with minor allele frequency (MAF) < 1% from the reference panel of CEU 
(Utah residents with ancestry from northern and western Europe) samples in the 1000 Genome Project. Thus, 
the number of SNPs was reduced to 2.5 million. Further QC criteria for excluding SNPs from the analysis were: 
(1) SNPs with more than 10% negative probe scores; (2) a sum of the mean raw red and green intensity values less 
than 1200 for each array (to ensure calibration); (3) SNPs with a small number of expected probes in pools (SNPs 
with MAF between 1–5% required at least half of the expected number of probes, and SNPs with MAF > 5% 
required at least a third; the expected number of probes was calculated as the average number of probes per pool 
per SNP multiplied by the number of samples in each pool); (4) non-autosomal SNPs; (5) SNPs where the vari-
ance of the estimated allele frequency was significantly different between all pools. After applying these QC filters, 
a total of 1,940,408 SNPs were retained for further analysis. A GWAS was carried out between responders and 
non-responders from three different baseline VA categories and then results were combined in a meta-analysis, 
which included 225 responders and 60 non-responders.
Second Phase - Technical Replication in the Melbourne Discovery Cohort. In the 2nd phase, the 
most interesting associations found in the pooled DNA GWAS were validated by undertaking individual gen-
otyping of the original 285 samples, plus the inclusion of the additional 12 patient samples that subsequently 
became available whose initial concentration was not enough for the pooling GWAS. These samples were geno-
typed individually for 44 SNPs using the MassArray platform (Agena Bioscience, San Diego, CA) and performed 
as previously described36.
Third Phase - Replication in an Independent Cohort of European Descent. In the third phase of 
the study, SNPs that showed association (p < 0.05 after correction for multiple testing) in the 2nd phase of the study 
were analysed in an independent ranibizumab-treated AMD cohort of European descent. DNA was extracted and 
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quantified in Nijmegen, the Netherlands. Subsequently, DNA samples of a total of 376 AMD patients were geno-
typed in Melbourne using the MassArray platform (Agena Bioscience, San Diego, CA) as previously described36.
Statistical analysis. Linear regression was undertaken to assess the role of non-genetic factors (potential 
cofounders), including age, sex, smoking status, CNV size, lesion type, number of injections and baseline VA, on 
the dependent variable “change in VA” at 3 and 6 months respectively.
The GWAS of pooled DNA was undertaken at the Queensland Institute of Medical Research (QIMR) as pre-
viously described37. A customised pipeline developed at QIMR was used for data analysis37,38. Briefly, a GWAS 
was run within each pool comparison, i.e. a linear model based approach was used for association between SNP 
and allele frequency difference in responder compared to non-responder pools accounting for pooling errors. 
A meta-analysis was performed summarising the GWAS results from the multiple pool comparisons, weighted 
by inverse variances. Finally, we applied post-analysis checks to the meta-analysis results in order to reduce the 
chance of false positive findings, filtering any SNP that had results from only one of the multiple pool compari-
sons and those with large discrepancies in association results of the SNP itself and its proxies.
For individual genotyping data, logistic regression was used to assess differences in allele frequency between 
the responder and non-responder groups (defined in the same manner as for the GWAS) and adjusted for base-
line VA in the discovery cohort and baseline VA and age at first injection in the replication cohort. In this repli-
cation cohort, different treatment regimens were administered after the 3 initial monthly injections. Therefore, 
we stratified the analysis for the replication cohort into two groups; pro-re-nata and treat-and-extend. These 
groups consisted of 215 pro re nata (Nijmegen and Cologne) and 47 treat-and-extend (Montreal) patients respec-
tively. Results are reported as odds ratios (OR), 95% confidence intervals (95% CI) and p value with statistical 
significance being defined as p < 0.05 following Bonferroni correction for multiple testing. For the analyses, the 
statistical software Plink V1.07 (http://pngu.mgh.harvard.edu/~purcell/plink/) and SPSS IBM SPSS Statistics for 
Windows, version 20.0 (IBM Corp., Armonk, New York, USA) were used. To prevent any possible confounding, 
the analyses performed in the both the Melbourne discovery and the replication cohort were corrected for base-
line VA.
Meta-analysis of the discovery and replication cohorts was performed using Metal software39. For 3 month 
meta-analysis all the patients from Melbourne discovery and the replication cohort were included because they 
all were treated with 3 initial doses of anti-VEGF injections while for the 6 months analysis we considered the fact 
that the Melbourne discovery cohort was treated using a pro re nata strategy. Therefore, we included only the 215 
pro re nata treated patients from Nijmegen and Cologne and excluded the 47 patients from Montreal who were 
treated with a treat-and-extend regimen.
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